Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Amgen Files Erenumab for Migraine Prevention in Japan
September 17, 2020
- SanBio to Start Talks with PMDA over Late-Stage Study of SB623 in Ischemic, Hemorrhagic Strokes: COO
September 17, 2020
- Prescriptions for Respiratory Meds, Antibiotics Down Over 30% in August: Survey
September 16, 2020
- Daiichi Sankyo Begins PII Study of ADC Patritumab for HER3-Positive Colorectal Cancer
September 16, 2020
- Novartis’ Mayzent now Available in Japan for Secondary Progressive MS
September 15, 2020
- J-TEC Files Mucosal Cell Sheet for Corneal Epithelial Stem Cell Deficiency in Japan
September 15, 2020
- Incyte Files Japan NDA for Pemigatinib for Cholangiocarcinoma
September 15, 2020
- Lilly Japan to Run Its First Voluntary Redundancy Program, 10% of Sales Force Targeted?
September 15, 2020
- AstraZeneca, PMDA Discussing Restart of COVID-19 Vaccine Trial in Japan
September 14, 2020
- Additional Dosage of Edoxaban Filed in Japan for Elderly with High Bleeding Risk
September 14, 2020
- Nihon Chouzai’s Standard Formulary Service Expands to 17 Therapeutic Classes, Monitor Hospitals Moving to Craft Own Lists
September 11, 2020
- 1st Japanese COVID-19 Patient Enrolled in Global PIII of Ultomiris: Alexion
September 11, 2020
- Enspryng Reduces Risk and Severity of Relapse by 79% in NMOSD Patients: Chugai
September 11, 2020
- Chugai, Takeda to Join Global PIII of Tecentriq/Cabometyx Combo in Japan
September 11, 2020
- Hisamitsu Seeks Label Expansion for Fentos Tape to Pediatric Cancer Pain
September 11, 2020
- MSD Files Keytruda for MSI-H Colorectal Cancer
September 11, 2020
- RegeNephron, Kirin Join Hands on Cell Therapy Process Development
September 10, 2020
- Takeda to Divest Non-Core Products Sold in Europe, Canada to Cheplapharm
September 10, 2020
- Japan Ethical Drug Sales Down 4.9% in July: Crecon
September 9, 2020
- SymBio Setting Up Standalone Sales System for Treakisym in Japan
September 9, 2020
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…